Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
about
Conformational equilibria in monomeric alpha-synuclein at the single-molecule levelRelationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicityThe homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant α-synuclein-induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteinsDequalinium-induced protofibril formation of alpha-synucleinThe H50Q mutation enhances α-synuclein aggregation, secretion, and toxicityGaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathiesFK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53TMolecular determinants of α-synuclein mutants' oligomerization and membrane interactionsParkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradationp25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathiesInteractions between fatty acids and alpha-synucleinMisfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathiesSecondary structure and dynamics of micelle bound beta- and gamma-synucleinIntrabody and Parkinson's diseaseResidual structure, backbone dynamics, and interactions within the synuclein familyParkin counteracts symptoms in a Drosophila model of Parkinson's disease.Definition of a molecular pathway mediating α-synuclein neurotoxicitySystematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activitiesAdaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbationsFish Synucleins: An UpdateTranscriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's diseaseMolecular chaperones and co-chaperones in Parkinson diseaseExploring the accessible conformations of N-terminal acetylated α-synucleinGenetically engineered mouse models of Parkinson's diseaseThe complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's diseasePathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body diseaseAlpha-synuclein biology in Lewy body diseasesMitochondrial dysfunction and oxidative stress in Parkinson's diseasePropagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.The Synaptic Function of α-SynucleinMore than a Rumor Spreads in Parkinson's DiseaseAlpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body DisordersThe contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseAlpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical ApplicationThe phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's diseaseThe parkin-like human homolog of Drosophila ariadne-1 (HHARI) can induce aggresome formation in mammalian cells and is immunologically detectable in Lewy bodiesProspects for new restorative and neuroprotective treatments in Parkinson's diseaseMicrotubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filamentsCasein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation
P2860
Q21563559-941ACF21-D385-45A4-AE9E-48F7E8504C0FQ24293089-ECB730EC-C2B4-4E1E-8427-FE8539738B81Q24295205-B2DFC667-0323-4BF0-84B4-E79B8D3657B0Q24298122-50AD1EDA-6148-461B-B661-1CF2A094F23BQ24299289-5E46E7E1-193B-4D46-82A0-7C708CA9A59BQ24307627-CB6EEC1B-4D25-4785-A3C2-88133CB88AD8Q24311758-3BE3C2CB-1A5D-41EE-8FA5-264FD8C81C4BQ24312185-95163A8C-4609-4D79-8068-E9D807E044ADQ24312713-3E8AE148-B36B-429A-85E4-56F40504433AQ24320549-6C9A09FD-00DF-4F7E-BFA1-670141CAFC37Q24336967-5B279ED6-69BB-4536-A223-E1597A82AD2CQ24554351-CDCE3DB7-483A-480E-80AB-B2628E674636Q24647859-256C2D09-B698-4AD5-8935-06759B72A107Q24653530-7F19FB52-36C5-46F1-9A1C-91D213190FE1Q24671058-3D2F60C4-4D07-4D46-93E9-0125AEFD964BQ24803129-9987ED3D-9B52-4B5F-ADC5-D53C15C33CC9Q26269832-B7F358DC-8E29-4F5B-BDFC-25016FA6B808Q26269871-C7E3F388-3260-4D44-8097-DFE19AE6398FQ26765956-76964FA7-222C-47B5-9F12-57D1B36A69A1Q26777065-5E3B5C23-C368-4E56-B3D0-70AB3B70D937Q26796502-A92F804E-2693-413A-AB4F-1562712AF006Q26828834-FA7FCFC3-D83E-47BB-A1FA-93A53F4FAB72Q26852660-886B7EDB-1D02-4EA2-90A8-A96217030FFDQ26852964-F1734F4F-EDEF-4DAF-AE40-289172BCB98AQ26853537-D9F1B98B-DDF1-4747-A4A4-0A1FE67D708FQ26853610-E1A53C38-10C0-4236-A491-C58687F29970Q27003541-E27F7D4E-2761-4179-B878-5E8D373D66EFQ27014051-0856A77A-6C59-417B-A3F1-49D66D893368Q27322513-D3801BB6-DB03-4DBC-91CC-BB0E389FF834Q27686837-D378A0AA-FCB6-4022-A968-62B9139933E8Q27694711-BD667C26-45DE-4AD7-9D1B-7FD30EFD5176Q28066571-8AF44B05-8E90-405E-944A-603679395147Q28067429-B930D656-2E40-4E41-B3AC-DDE7C9854271Q28068464-09BFF53B-A2FA-4CBA-A40C-F9E04BF3DEE7Q28079911-99D23553-8341-4F43-B940-9417C449EFC8Q28087330-8D51D716-57B4-405A-9217-794914F18494Q28117293-6EF6F747-83BD-450C-AF9C-E18D6A5CB3F2Q28138668-F788EFF9-2DAF-456A-B7EE-FED34B92C366Q28141728-D3F8A378-974B-4B26-8D4F-8F53593031ECQ28188133-544541D9-BD34-4E9E-BB9F-87FB77AE158A
P2860
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Accelerated in vitro fibril fo ...... early-onset Parkinson disease.
@en
Accelerated in vitro fibril fo ...... early-onset Parkinson disease.
@nl
type
label
Accelerated in vitro fibril fo ...... early-onset Parkinson disease.
@en
Accelerated in vitro fibril fo ...... early-onset Parkinson disease.
@nl
altLabel
Accelerated in vitro fibril fo ...... early-onset Parkinson disease
@en
prefLabel
Accelerated in vitro fibril fo ...... early-onset Parkinson disease.
@en
Accelerated in vitro fibril fo ...... early-onset Parkinson disease.
@nl
P2093
P356
P1433
P1476
Accelerated in vitro fibril fo ...... early-onset Parkinson disease.
@en
P2093
P2888
P304
P356
10.1038/3311
P407
P577
1998-11-01T00:00:00Z